Frontlight ResearchEarly access
SuspendedNo phase
Safety and Effectiveness of the ATC System in the Treatment of Acute PE
Key facts
- Who runs it
- Akura Medical
- Where
- Brazil and Dominican Republic3 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Suspended
- People taking part
- 30 people, planned
- Started
- 15 May 2024
- Expected to end
- May 2027
- Type of study
- Interventional
- Treatments tested
- ATC System
- Record updated
- 31 August 2026
- Why it stopped
- Enrollment temporarily paused pending device resupply to sites. Enrollment is expected to resume to reach the target sample size following the recently approved protocol amendment. The pause is not related to subject safety or device performance.
Who can take part
- Age
- 18 years to 90 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 34 criteriaShow less
Who can take part
- Patient is ≥ 18 and ≤ 90 years old
- Clinical signs and symptoms consistent with acute PE for < 14 days
- CTA evidence of proximal PE
- RV/LV ratio > 0.9
- Systolic BP ≥90 mmHg without the need for vasopressors
- Stable heart rate (HR) < 130 BPM prior to procedure
- Patient is deemed medically eligible for interventional procedure(s), per investigator guidelines and clinical judgment
- Subject or legally authorized representative (LAR) is willing and able to provide written informed consent prior to receiving any non-standard of care protocol specific procedures
Who cannot take part
- Prior PE < 180 days from index procedure
- Thrombolytic use < 30 days prior to baseline CTA
- Major trauma injury severity score (ISS) >15 prior to screening assessment
- Presence of intracardiac lead in right ventricle or atrium placed within 6 months prior to screening assessment
- Cardiovascular or pulmonary surgery within 7 days of index procedure
- Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated
- Current participation in another investigational drug or device treatment study
- Pulmonary hypertension with peak pulmonary artery systolic pressure (PASP) >70 mmHg by right heart catheterization
- Actively progressing cancer treated by chemotherapeutics
- Known bleeding diathesis or coagulation disorder
- History of severe or chronic pulmonary arterial hypertension
- History of decompensated heart failure
- History of underlying lung disease that is oxygen dependent
- History of chest irradiation
- History of heparin-induced thrombocytopenia (HIT)
- Life expectancy <90 days, as determined by investigator such as stage 4 cancer, frailty or severe COVID infections
- Platelets count <100,000/µL
- Serum creatinine >1.8 mg/dL
- International normalized ratio (INR) >3
- History of chronic left heart disease with left ventricular ejection fraction ≤ 30%
- FiO2 requirement >40% or >6 LPM to keep oxygen saturation >90%
- Hematocrit <28%
- Left bundle branch block
- Contraindication to systemic or therapeutic doses of anticoagulants
- Imaging evidence or other evidence that suggest, in the opinion of the investigator, the Subject is not appropriate for aspiration thrombectomy intervention
- Female who is pregnant or nursing
This trial has no sites in United States.
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is a prospective, single-arm, interventional, multicenter study to evaluate the safety and effectiveness of the ATC System in subjects with acute pulmonary embolism (PE).
The group in the trial
- Patients with Acute Pulmonary EmbolismTreatment being tested
Patients undergoing mechanical thrombectomy for acute pulmonary embolism.
Treatment: ATC System
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Safety and Effectiveness of the ATC System in the Treatment of Acute Pulmonary Embolism
- Record updated
- 31 August 2026